Identification of a novel prognostic marker ADGRG6 in pancreatic adenocarcinoma: multi-omics analysis and experimental validation
ADGRG6 may serve as a novel prognostic marker and a therapeutic targets for PAAD, playing a crucial role in the proliferation, metastasis, and immune marker regulation of PAAD through elevating protein level of mutated p53.
Authors
- Yan-yan Zhan (ORCID: https://orcid.org/0000-0003-3962-0349)
- Yuxin Bao
- Xiaolei Cheng (ORCID: https://orcid.org/0000-0001-7233-5238)
- Yangtaobo Li
- Pingli Mo (ORCID: https://orcid.org/0000-0002-4913-2042)
- Han Wu (ORCID: https://orcid.org/0000-0002-8235-3971)
- Daxuan Wang
- Wenqing Zhang (ORCID: https://orcid.org/0000-0002-5119-1658)
- Haoran Zhang (ORCID: https://orcid.org/0000-0002-7929-9003)
- Jin Shang (ORCID: https://orcid.org/0000-0002-7897-7095)
- Huajie Liu (ORCID: https://orcid.org/0000-0002-1359-7200)
- Mingqing Zhang (ORCID: https://orcid.org/0000-0001-5486-2026)
- Zixuan Ma (ORCID: https://orcid.org/0000-0002-3965-4939)
- Yaosheng Xiao (ORCID: https://orcid.org/0000-0002-5286-7680)
- Zhaozhang Huang
Institutions
- Xiamen University (CN)
- Fujian Provincial Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-03-27
- DOI
- https://doi.org/10.3389/fimmu.2025.1530789
- Citations
- 1
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Fujian Province